WalterHanelMD

Physician

Dr. Hanel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Start of enrollment: 2021 Sep 01
Active, not recruiting
Phase 1
Roles: Sponsor-Investigator, Principal Investigator, Contact

PubMed

2 citations
Impact of circulating lymphoma cells at diagnosis on outcomes in patients with marginal zone lymphoma: a multicenter cohort study.
Kaitlin Annunzio, Natalie S Grover, Rina Li Welkie, Pallawi Torka, Marcus P Watkins
Blood Advances. 2023-11-28
2 citations
Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation.
Sairah Ahmed, Qiuhong Zhao, Walter Hanel, Muzaffar H. Qazilbash, Krina K. Patel
Hematological Oncology. 2021-11-11
34 citations
Emerging therapies in mantle cell lymphoma
Walter Hanel, Narendranath Epperla
Journal of Hematology & Oncology. 2020-06-17

Abstracts/Posters

Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
Walter Hanel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Targeting Hypersumoylation in Mantle Cell Lymphoma
Walter Hanel, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019